Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2780301 + Gemcitabine in Advanced Cancer
NCT02018874Phase 1Completed
- Sponsor
- Gustave Roussy
- Start
- Sep 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY2780301 in solid tumor, non-Hodgkin lymphoma (NHL) and ovarian cancer, sponsored by Gustave Roussy. Primary endpoints: Safety at 4 weeks and Efficacy. Started Sep 2013; status: completed.
02
Drugs
LY2780301
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)ovarian cancer
Beyond the preview
Go deeper on NCT02018874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02018874.